MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
15.01
-0.18 (-1.18%)
At close: Sep 4, 2026, 4:00 PM EDT
15.04
+0.03 (0.20%)
After-hours: Sep 4, 2026, 7:30 PM EDT
MoonLake Immunotherapeutics Employees
MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year.
Employees
130
Change (1Y)
30
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$2,028,200
Market Cap
1.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 30 | 30.00% |
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| MeiraGTx Holdings | 393 |
| Omeros | 175 |
| Janux Therapeutics | 113 |
| ORIC Pharmaceuticals | 111 |
| Odyssey Therapeutics | 100 |
| Savara | 70 |
MLTX News
- 21 days ago - MoonLake price target raised to $50 from $45 at H.C. Wainwright - TheFly
- 4 weeks ago - MoonLake's psoriatic arthritis drug meets key goals in late-stage trial - Reuters
- 4 weeks ago - MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c) - TheFly
- 4 weeks ago - MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 - TheFly
- 4 weeks ago - MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - MoonLake Immunotherapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - MoonLake Immunotherapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - MoonLake Immunotherapeutics 9M share Secondary priced at $20.00 - TheFly